Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study

Journal article


Publication Details

Author(s): Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Draeger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaarll JPM, Van Criekinge W, Schalken JA
Journal: Prostate Cancer and Prostatic Diseases
Publication year: 2019
Volume: 22
Journal issue: 1
Pages range: 101-109
ISSN: 1365-7852


Abstract

Background Low specificity of prostate-specific antigen results in a considerable number of unnecessary prostate biopsies in current practice. SelectMDx (R) predicts significant prostate cancer upon biopsy and is used to reduce the number of unnecessary initial prostate biopsies. Furthermore, potential overtreatment of insignificant prostate cancer can be reduced. Besides the diagnostic accuracy of the test, also the context in a specific country determines the potential health benefit and cost-effectiveness. Therefore, the health benefit and cost-effectiveness of SelectMDx were assessed in France, Germany, Italy, and Spain.


External institutions with authors

European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
Hospices Civils de Lyon (CHU)
Hospital Universitario Miguel Servet
Hospital Universitario Puerta de Hierro - Majadahonda
Ludwig-Maximilians-Universität (LMU)
MDxHealth Netherlands
MedValue
Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC)
Universiteit Gent (UGent) / Ghent University
Valencia Oncology Institute Foundation / Fundación Instituto Valenciano de Oncología (IVO)


How to cite

APA:
Govers, T.M., Hessels, D., Vlaeminck-Guillem, V., Schmitz-Draeger, B.J., Stief, C.G., Martinez-Ballesteros, C.,... Schalken, J.A. (2019). Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. Prostate Cancer and Prostatic Diseases, 22(1), 101-109. https://dx.doi.org/10.1038/s41391-018-0076-3

MLA:
Govers, Tim M., et al. "Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study." Prostate Cancer and Prostatic Diseases 22.1 (2019): 101-109.

BibTeX: 

Last updated on 2019-13-03 at 18:23